Renal Failure Patients in Disasters

Lempert, Kenneth D.; Kopp, Jeffrey B.

doi:10.1017/dmp.2018.142

Cited by 13 publications

(11 citation statements)

References 71 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A sudden spike in cases of COVID-19 or future entities might cause unforeseen shortages of RRT devices and/or RRT disposables and fluids 118 . Additionally, supply chain security may be compromised, further augmenting local shortages 119 , 120 . As part of a local surge response, use of a wider variety of acute RRT modalities (CRRT, PIRRT, IHD and acute PD) may be needed to maximize the number of patients who can receive RRT.…”

Section: Renal Replacement Therapymentioning

confidence: 99%

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

et al. 2020

View full text Add to dashboard Cite

Kidney involvement in patients with coronavirus disease 2019 (COVID-19) is common, and can range from the presence of proteinuria and haematuria to acute kidney injury (AKI) requiring renal replacement therapy (RRT; also known as kidney replacement therapy). COVID-19-associated AKI (COVID-19 AKI) is associated with high mortality and serves as an independent risk factor for all-cause in-hospital death in patients with COVID-19. The pathophysiology and mechanisms of AKI in patients with COVID-19 have not been fully elucidated and seem to be multifactorial, in keeping with the pathophysiology of AKI in other patients who are critically ill. Little is known about the prevention and management of COVID-19 AKI. The emergence of regional ‘surges’ in COVID-19 cases can limit hospital resources, including dialysis availability and supplies; thus, careful daily assessment of available resources is needed. In this Consensus Statement, the Acute Disease Quality Initiative provides recommendations for the diagnosis, prevention and management of COVID-19 AKI based on current literature. We also make recommendations for areas of future research, which are aimed at improving understanding of the underlying processes and improving outcomes for patients with COVID-19 AKI.

show abstract

Section: Renal Replacement Therapymentioning

confidence: 99%

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

et al. 2020

View full text Add to dashboard Cite

show abstract

“…About a quarter of hemodialysis patients in New Orleans developed post-traumatic stress disorder after hurricane Katrina [ 76 ]. Several other examples of exposure of the hemodialysis population to environmental disasters exist [ 77 ]. These disasters provide an interesting opportunity for studying the association between NPY levels and this disorder.…”

Section: Introductionmentioning

confidence: 99%

Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges

Zoccali

Ortíz

Blumbyte

et al. 2021

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is a 36-amino-acid peptide member of a family also including peptide YY and pancreatic polypeptide which are all ligands to Gi/Go coupled receptors. NPY regulates several fundamental biologic functions including appetite/satiety, sex and reproduction, learning and memory, cardiovascular and renal function and the immune function. The mesenteric circulation is a major source of NPY in the blood in man and this peptide is considered a key regulator of the gut-brain cross-talk. A progressive rise in circulating NPY accompanies the progression of CKD toward kidney failure and NPY robustly predicts cardiovascular events in this population. Furthermore, NPY is suspected as a possible player in the accelerated cognitive function decline and dementia in patients with CKD and in dialysis patients. In theory, Interfering with the NPY system has relevant potential for the treatment of diverse diseases from cardiovascular and renal diseases to diseases of the central nervous system. Pharmaceutical formulations for effective drug delivery and cost as well as the complexity of diseases potentially addressable by NPY/NPY antagonists have been a problem until now. This in part explains the slow progress of knowledge about the NPY system in the clinical arena. There is now a renewed research interest on the NPY system in psycho pharmacology and in pharmacology in general and new studies and a new breed of clinical trials may eventually bring the expected benefits in human health by drugs interfering with this system.

show abstract

“…In addition, climate change results in extreme weather events, which can provoke displacement and threaten food security. These effects afflict most profoundly individuals affected by illness and poverty, among whom people with kidney disease are highly vulnerable 107 . By 2019, the Paris Climate Agreement had been ratified by 185 parties, offering hope that global collaboration at national levels will bring progress 2 .…”

Section: Energy Decarbonization and Industrymentioning

confidence: 99%